Gregory Harmon, MD
Ophthalmology · New York, NYNPI 1386731479
Payments from drug & device makers
Across 137 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$860
- Bausch & Lomb Americas Inc.$611
- Johnson & Johnson Surgical Vision, Inc.$431
- Alcon$345
- Kala Pharmaceuticals, Inc.$300
- Novartis$210
- plus $985 from 13 others
What the payments were for
- Food & beverage$3,68498%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $860 |
| Bausch & Lomb Americas Inc. | 11 | $611 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $431 |
| Alcon | 11 | $345 |
| Kala Pharmaceuticals, Inc. | 13 | $300 |
| Novartis | 13 | $210 |
| Tarsus Pharmaceuticals, Inc. | 7 | $191 |
| Oyster Point Pharma, Inc. | 5 | $131 |
| Dompe US, Inc. | 5 | $124 |
| Amgen(2 entities) | 5 | $112 |
| Sun Pharmaceutical Industries Inc. | 4 | $107 |
| Thea Pharma Inc. | 4 | $95 |
| Sight Sciences, Inc. | 3 | $78 |
| Biotissue Holdings Inc. | 2 | $45 |
| Glaukos Corporation | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Ivantis, Inc | 1 | $21 |
| Rxsight Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$406
- AcrySof IQ VIVITY IOL$136
- Tecnis Simplicity$125
- VYZULTA$124
- DURYSTA$112
How this compares
$3,742 in reported general payments places this provider in the 70th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 731 | $852,825 |
| XiidraLifitegrast | 292 | $328,419 |
| LumiganBimatoprost | 297 | $162,285 |
| TyrvayaVarenicline Tartrate | 131 | $151,073 |
| MieboPerfluorohexyloctane/Pf | 123 | $140,402 |
| RocklatanNetarsudil Mesylat/Latanoprost | 242 | $139,865 |
| CequaCyclosporine | 140 | $122,678 |
| Alphagan PBrimonidine Tartrate | 212 | $115,393 |
| CombiganBrimonidine Tartrate/Timolol | 257 | $115,290 |
| VyzultaLatanoprostene Bunod | 170 | $104,863 |
| RhopressaNetarsudil Mesylate | 170 | $99,263 |
| Cyclosporine | 142 | $55,145 |
| ProlensaBromfenac Sodium | 150 | $53,131 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 148 | $48,894 |
| ZioptanTafluprost/Pf | 104 | $42,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $860 | $1,245,7941,497 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $611 | $573,684585 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $131 | $151,073131 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $107 | $122,678140 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax | $22 | $72,027259 claims |
| AlconSimbrinza, Azopt | $345 | $70,342177 claims |
| NovartisTravatan Z | $210 | $22,17728 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $191 | $22,13112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.